Preserved in Portico This version is not peer-reviewed
Liquid Biopsies in Epilepsy: Biomarkers for Etiology, Diagnosis, Prognosis, and Therapeutics
: Received: 23 August 2021 / Approved: 26 August 2021 / Online: 26 August 2021 (16:40:54 CEST)
A peer-reviewed article of this Preprint also exists.
Journal reference: Human Cell 2021
Epilepsy is one of the most common disorders of the central nervous system, impacting nearly 50 million people around the world. Heterogeneous in nature, epilepsy presents in children and adults alike. Currently, surgery is the only treatment that can cure epilepsy. However, not all individuals are eligible or have successful outcomes. Difficulty in accessing samples of human brain tissue along with advances in sequencing technology have driven researchers to investigate sampling liquid biopsies in blood, serum, plasma, and cerebrospinal fluid within the context of epilepsy. Liquid biopsies provide minimal or non-invasive sample collection approaches and can be assayed relatively easily across multiple time points, unlike tissue-based sampling. Various efforts have investigated circulating nucleic acids from these samples including microRNAs, cell-free DNA, transfer RNAs, and long non-coding RNAs. Here, we review nucleic acid-based liquid biopsies in epilepsy to improve understanding of etiology, diagnosis, prediction, and therapeutic monitoring.
liquid biopsy; epilepsy; circulating biomarkers; cfDNA; lncRNA; tRNA; miRNA; diagnosis; prognosis; therapeutics
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.